Repros Therapeutics Company Profile (NASDAQ:RPRX)

About Repros Therapeutics

Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: RPRX
  • CUSIP: 76028H20
Key Metrics:
  • Previous Close: $1.21
  • 50 Day Moving Average: $1.27
  • 200 Day Moving Average: $1.71
  • 52-Week Range: $0.81 - $3.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.95
  • P/E Growth: -0.06
  • Market Cap: $30.76M
  • Outstanding Shares: 25,425,000
  • Beta: -0.82
Profitability:
  • Net Margins: -39,128.00%
  • Return on Equity: -151.63%
  • Return on Assets: -127.79%
Debt:
  • Current Ratio: 4.63%
  • Quick Ratio: 4.63%
Additional Links:
Companies Related to Repros Therapeutics:

Analyst Ratings

Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $1.50 (23.97% upside)

Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
DateFirmActionRatingPrice TargetDetails
1/30/2017S&P Equity ResearchBoost Price Target$1.22 -> $1.50View Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesUpgradeNeutral -> BuyView Rating Details
2/9/2016Piper Jaffray CompaniesReiterated RatingNeutralView Rating Details
12/4/2015Brean CapitalReiterated RatingHoldView Rating Details
10/30/2015Bank of America CorpDowngradeNeutral -> UnderperformView Rating Details
7/28/2015LaidlawReiterated RatingBuy$28.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Repros Therapeutics (NASDAQ:RPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/8/2016Q3 2016($0.18)($0.17)ViewN/AView Earnings Details
8/9/2016Q216($0.20)($0.18)ViewN/AView Earnings Details
5/10/2016Q1($0.22)($0.20)ViewN/AView Earnings Details
3/14/2016Q4($0.27)($0.26)ViewN/AView Earnings Details
11/9/2015Q3($0.29)($0.27)ViewN/AView Earnings Details
8/10/2015Q2($0.26)($0.32)ViewN/AView Earnings Details
3/16/2015Q414($0.34)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.39)($0.32)ViewN/AView Earnings Details
8/11/2014($0.37)($0.38)ViewN/AView Earnings Details
5/12/2014Q114($0.35)($0.37)ViewN/AView Earnings Details
3/13/2014Q413($0.29)($0.31)ViewN/AView Earnings Details
8/7/2013Q213($0.40)($0.38)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.35)($0.41)ViewN/AView Earnings Details
3/18/2013Q412($0.28)($0.47)$0.00 million$0.00 millionViewN/AView Earnings Details
11/13/2012Q312($0.24)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repros Therapeutics (NASDAQ:RPRX)
Current Year EPS Consensus Estimate: $-0.72 EPS
Next Year EPS Consensus Estimate: $-0.62 EPS

Dividends

Dividend History for Repros Therapeutics (NASDAQ:RPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Repros Therapeutics (NASDAQ:RPRX)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 27.04%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Joseph PodolskiInsiderBuy20,000$1.60$32,000.00View SEC Filing  
2/18/2016Joseph PodolskiCEOBuy10,000$0.93$9,300.00View SEC Filing  
1/7/2016Joseph PodolskiCEOBuy11,677$1.18$13,778.86View SEC Filing  
11/12/2014Joseph PodolskiCEOBuy4,700$9.42$44,274.00View SEC Filing  
11/12/2014Katherine AndersonCFOBuy3,500$9.41$32,935.00View SEC Filing  
8/14/2014Joseph PodolskiCEOBuy2,100$13.91$29,211.00View SEC Filing  
8/14/2014Katherine AndersonCFOBuy2,000$13.85$27,700.00View SEC Filing  
10/25/2013Joseph PodolskiCEOBuy3,000$18.03$54,090.00View SEC Filing  
10/25/2013Katherine AndersonCFOBuy1,000$17.90$17,900.00View SEC Filing  
10/10/2013Katherine AndersonCFOBuy1,000$23.77$23,770.00View SEC Filing  
2/1/2013Katherine AndersonCFOBuy1,000$11.89$11,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Repros Therapeutics (NASDAQ:RPRX)
DateHeadline
News IconShare Watch: Examining the Levels for Repros Therapeutics Inc. (NASDAQ:RPRX) - Baldwin Journal (NASDAQ:RPRX)
baldwinjournal.com - February 25 at 2:22 AM
News IconAre Analysts Optimistic About Where Repros Therapeutics Inc. (NASDAQ:RPRX) is Heading? - Winfield Review (NASDAQ:RPRX)
winfieldreview.com - February 25 at 2:22 AM
News IconRepros Therapeutics Inc RPRX Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:RPRX)
www.bioportfolio.com - February 20 at 6:49 PM
News IconMA Watch on Shares of Repros Therapeutics Inc. (RPRX) - Rives Journal (NASDAQ:RPRX)
rivesjournal.com - February 14 at 6:04 AM
News IconChart Level Analysis on Shares of Repros Therapeutics Inc. (RPRX) - Piedmont Register (NASDAQ:RPRX)
piedmontregister.com - February 8 at 11:34 PM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi (NASDAQ:RPRX)
biz.yahoo.com - February 8 at 11:34 PM
streetinsider.com logoRepros Therapeutics (RPRX) Names Larry Dillaha as Interim CEO - StreetInsider.com (NASDAQ:RPRX)
www.streetinsider.com - February 4 at 7:41 PM
bizjournals.com logoCEO leaves Woodlands-based drug company; interim named (NASDAQ:RPRX)
www.bizjournals.com - February 3 at 11:38 PM
streetinsider.com logoRepros Therapeutics (RPRX) Names Larry Dillaha as Interim CEO (NASDAQ:RPRX)
www.streetinsider.com - February 3 at 3:10 AM
us.rd.yahoo.com logo9:16 am Repros Therapeutics President and CEO Joseph S. Podolski is leaving his position to pursue other interests; Larry Dillaha, M.D., CEO of CavtheRx, was appointed interim President and CEO, effective immediately (NASDAQ:RPRX)
us.rd.yahoo.com - February 3 at 3:10 AM
streetinsider.com logoRepros Therapeutics (RPRX) Granted FDA End of Phase 2 Meeting on Proellex (NASDAQ:RPRX)
www.streetinsider.com - February 1 at 3:11 AM
News IconInvestor Arena: Keeping an Eye on Repros Therapeutics Inc. (RPRX) - Sherwood Daily (NASDAQ:RPRX)
sherwooddaily.com - January 31 at 10:09 PM
News IconStock Vacillating as Volatility Hits a High Point For Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 31 at 10:09 PM
marketexclusive.com logoRepros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Regulation ... - Market Exclusive (NASDAQ:RPRX)
marketexclusive.com - January 31 at 1:26 AM
streetinsider.com logoRepros Therapeutics (RPRX) Granted FDA End of Phase 2 Meeting on Proellex - StreetInsider.com (NASDAQ:RPRX)
www.streetinsider.com - January 30 at 8:25 PM
finance.yahoo.com logo9:15 am Repros Therapeutics announces that the FDA has granted an 'end of Phase 2' meeting to discuss the Phase 3 requirements to demonstrate both efficacy and safety for the development of Proellex for the treatment of uterine fibroids (NASDAQ:RPRX)
finance.yahoo.com - January 30 at 8:25 PM
finance.yahoo.com logoFDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids (NASDAQ:RPRX)
finance.yahoo.com - January 30 at 8:25 PM
News IconEarnings in Full Force, Analysts Take Aim at Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 29 at 12:47 AM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Repros Therapeutics Inc. (NASDAQ:RPRX) - Nelson Research (NASDAQ:RPRX)
nelsonobserver.com - January 29 at 12:47 AM
News IconPulling Back the Curtain on Analysts Long-Term Stock Predictions For Repros Therapeutics Inc. (NASDAQ:RPRX) - Aiken Advocate (NASDAQ:RPRX)
aikenadvocate.com - January 26 at 4:07 AM
News IconTrading Corner: Eye on Technical Levels for Repros Therapeutics Inc. (RPRX) - Sherwood Daily (NASDAQ:RPRX)
sherwooddaily.com - January 26 at 4:07 AM
News IconEnlivened Volatility Spotted in Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 26 at 4:07 AM
News IconTrading Sheet: Tracking Technicals for Repros Therapeutics Inc. (RPRX) - Sherwood Daily (NASDAQ:RPRX)
sherwooddaily.com - January 25 at 3:24 AM
News IconTechnical Trading: Focus on Shares of Repros Therapeutics Inc. (RPRX) - Sherwood Daily (NASDAQ:RPRX)
sherwooddaily.com - January 24 at 8:03 AM
News IconPriming The Pump: Stock Volatility Spotted in Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 24 at 8:03 AM
investornewswire.com logoRepros Therapeutics Inc. (NASDAQ:RPRX) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - January 23 at 8:56 AM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 23 at 8:56 AM
News IconTrump Sworn In as S&P Declined, How Did this Stock Perform This Week: Repros Therapeutics Inc. (NASDAQ:RPRX) - Aiken Advocate (NASDAQ:RPRX)
aikenadvocate.com - January 22 at 1:06 AM
News IconWatching the Technicals on Shares of Repros Therapeutics Inc. (RPRX) - Sherwood Daily (NASDAQ:RPRX)
sherwooddaily.com - January 21 at 4:11 AM
News IconA Keen Look at These Shares: Repros Therapeutics Inc. (NASDAQ ... - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - January 21 at 4:11 AM
News IconInvestor Probe: Watching Technicals for Repros Therapeutics Inc ... - Sherwood Daily (NASDAQ:RPRX)
sherwooddaily.com - January 20 at 6:33 AM
News IconIs This The Right Stock For Heady Investors: Repros Therapeutics Inc. (NASDAQ:RPRX) - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - January 20 at 6:33 AM
News IconTechnical Update on Shares of Repros Therapeutics Inc. (RPRX) - Sherwood Daily (NASDAQ:RPRX)
sherwooddaily.com - January 19 at 1:16 AM
News IconGearing Up For a Bull Run? Analysts Weigh in on Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 19 at 1:16 AM
News IconInvestors Swarm in on Repros Therapeutics Inc. (NASDAQ:RPRX) - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - January 18 at 12:58 AM
News IconAre Investors Circling This Stock? Analyst Projections Point to Continued Growth: Repros Therapeutics Inc. (NASDAQ ... - Aiken Advocate (NASDAQ:RPRX)
aikenadvocate.com - January 17 at 12:16 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Repros Therapeutics Inc. (NASDAQ:RPRX) - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - January 17 at 12:16 PM
News IconSpot-check on CCI and RSI for Repros Therapeutics Inc. (RPRX) - Sherwood Daily (NASDAQ:RPRX)
sherwooddaily.com - January 17 at 12:16 PM
News IconTracking Corporate Insiders: What Are They Doing With Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 17 at 12:16 PM
News IconIs the Needle Ready to Move on Repros Therapeutics Inc. (NASDAQ:RPRX) - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - January 17 at 12:16 PM
investornewswire.com logoRepros Therapeutics Inc. (NASDAQ:RPRX) Strong Sell Recommendations At {RATING_CNT_STRONG_SELLS:378}} - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - January 15 at 7:05 PM
News IconWill The Needle Move For Repros Therapeutics Inc. (NASDAQ:RPRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 15 at 8:34 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Repros ... - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 15 at 8:34 AM
News IconCan This Stock Pick Up Any Momentum: Repros Therapeutics Inc. (NASDAQ:RPRX) - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - January 12 at 2:56 AM
News IconAre Institutions Jumping Ship on Repros Therapeutics Inc. (NASDAQ:RPRX) - Wall Street Beacon (NASDAQ:RPRX)
wsbeacon.com - January 12 at 2:56 AM
News IconBargain Hunters Should Take a Look at Repros Therapeutics Inc ... - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - January 10 at 1:57 AM
News IconRepros Therapeutics Inc RPRX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RPRX)
www.bioportfolio.com - January 8 at 7:25 PM
investornewswire.com logoRepros Therapeutics Inc. (NASDAQ:RPRX) Strong Buy Recommendations At 1 - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - January 2 at 12:55 AM
News IconBounding Shares, What's Next for Repros Therapeutics Inc. (NASDAQ:RPRX) - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - December 30 at 8:31 AM
News IconStreetwise Investors Taking Note of Repros Therapeutics Inc ... - Prospect Journal (NASDAQ:RPRX)
prospectjournal.com - December 23 at 8:02 AM

Social

What is Repros Therapeutics' stock symbol?

Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."

Where is Repros Therapeutics' stock going? Where will Repros Therapeutics' stock price be in 2017?

1 equities research analysts have issued 12 month target prices for Repros Therapeutics' stock. Their forecasts range from $1.50 to $1.50. On average, they anticipate Repros Therapeutics' stock price to reach $1.50 in the next year.

When will Repros Therapeutics announce their earnings?

Repros Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Repros Therapeutics stock?

Repros Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (6.58%) and Renaissance Technologies LLC (2.82%).

Who bought Repros Therapeutics stock? Who is buying Repros Therapeutics stock?

Repros Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy Repros Therapeutics stock?

Shares of Repros Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Repros Therapeutics stock cost?

One share of Repros Therapeutics stock can currently be purchased for approximately $1.21.

Repros Therapeutics (NASDAQ:RPRX) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Earnings History Chart

Earnings by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Dividend History Chart

Dividend Payments by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Last Updated on 2/27/2017 by MarketBeat.com Staff